NEWTON, Mass., March 17, 2026 /PRNewswire/ -- GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, today announced that it has been selected to deliver a late-breaking oral presentation highlighting translational data of GV20-0251 at the American Association of...
GV20 Therapeutics Announces Late-Breaking Oral Presentation of GV20-0251 Translational Findings at the AACR Annual Meeting 2026
